Our Endogenous Tissue Restoration (ETR) platform
Xeltis’ implants enable a patient’s own natural healing system to restore a new blood vessel – a therapeutic process called Endogenous Tissue Restoration (ETR).
At the heart of Xeltis’ vascular restoration platform is Nobel prize-winning technology.
Using supramolecular chemistry, first developed from the laboratory of the renowned Prof. Jean-Marie Lehn, the novel polymer, free from intentionally introduced PFAS, is electrospun into microfibers to create implants which restore vascular function.
Watch world famous chemist Bert Meijer, who is also an independent adviser to Xeltis, on Optimum TV discussing the potential for supramolecular polymers in modern medicine.
Xeltis’ groundbreaking platform is the most significant breakthrough in vascular replacement technology in over 60 years.
Over time, our implants are gradually replaced by the patients’ own living healthy tissue.
Xeltis’ implant technology is backed by strong research conducted over many years.
Key findings to date across preclinical and clinical research have been low infection rates, high patency rates and reduced intervention rates and a consistent process of natural healing.
>
230
Implanted in >230 patients
>
25
>25 patients with 5 year follow up
>
180
>180 patients received aXess vascular access conduit
Watch Xeltis’s Chief Medical Officer, Paulo Neves speaking on Optimum TV about the successful clinical data from the aXess EU pivotal trial.
Watch on YouTube
Watch Xeltis Medical Advisory Board member Frans Moll speaking on Optimum TV highlighting the rising issue of PFAS in the medical industry.
Watch on YouTube
BENEFITS
Compared to existing treatments, Xeltis’ transformative vascular and valve implants offer:
Reduced reinterventions
Lower rates of infection and rejection
Scalability and ease of storage
Standard surgical techniques
Xeltis is developing medical devices to address key areas of unmet need in vascular replacement and break the cycle of complications and reinterventions.
Visit our Applications page to learn more.
Applications